Physician profile
Douglas D Macqueen
NPI 1427129543
$1,653.63
in general payments reported to CMS, 2019-2025
21 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $200 · 2021: $49.00 · 2022: $14.72 · 2023: $130 · 2024: $290 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867 · Education: $44.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.14 |
| Education | $44.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $283.97 | 2019-2020 | |
| Gilead Sciences, INC. | $204.33 | 2019-2025 | |
| Novo Nordisk INC | $180.42 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $150.61 | 2019-2025 | |
| Insmed, INC. | $115.57 | 2019-2025 | Arikayce, Brinsupri |
| Sun Pharmaceutical Industries INC. | $106.51 | 2023-2025 | Ilumya |
| Ferring Pharmaceuticals INC. | $93.98 | 2023-2024 | Rebyota |
| Viiv Healthcare Company | $80.84 | 2021-2025 | Cabenuva, Apretude |
| Allergan, INC. | $72.01 | 2019-2020 | |
| Ucb, INC. | $57.97 | 2019 | |
| Astellas Pharma US INC | $44.99 | 2025 | |
| Celgene Corporation | $44.84 | 2019 | |
| Merck Sharp & Dohme LLC | $36.07 | 2025 | Pifeltro, Capvaxive |
| Lilly USA, LLC | $33.48 | 2019-2025 | Zepbound, Mounjaro |
| Melinta Therapeutics, LLC | $29.77 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $26.19 | 2020 | |
| Sanofi Pasteur INC. | $24.60 | 2019 | |
| Sobi, INC | $21.03 | 2020 | |
| Paratek Pharmaceuticals, INC. | $16.26 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.70 | 2020 | |
| Radius Health, INC. | $14.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Macqueen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.